November 8, 2016 / 10:03 PM / in a year

BRIEF-Aeterna zentaris Q3 loss per share $0.61

Nov 8 (Reuters) - Aeterna Zentaris Inc :

* Aeterna Zentaris - believe have funds necessary to complete two pivotal clinical trials, to report top-line results on both, to file a nda for macrilen in first half of 2017

* Aeterna Zentaris reports third quarter 2016 financial and operating results

* Q3 loss per share $0.61 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below